Classement en actions
#38811
Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in... Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.
Prix de l'action
$0.20410523
Dernière synchronisation: 2024-04-30
Capitalisation boursière
$793.94K
Changement (1 jour)
42.54%
Échange Redx Pharma Plc (REDX)
Bénéfices pour Redx Pharma Plc (REDX)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Redx Pharma Plc, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Redx Pharma Plc de 2026 à 2026
Bénéfices à la fin de chaque année
| Année |
Bénéfices |
Changez |
|
Pas assez de données pour les dates fournies. |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise |
Bénéfices |
Différence de bénéfices |
Pays |
|
|
$5.27B |
-
|
US
|
|
|
$1.95B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
$3.01B |
-
|
BE
|
